American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears

The newly issued CPT^® codes establish the foundation for reimbursement of InGeneron’s Transpose^® RT cell therapy.

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical stage biotechnology company, today announced that the American Medical Association’s (AMA) Current Procedural Terminology (CPT^®) Editorial Panel has issued two new Category III CPT^® codes for the company’s autologous, adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tears. The newly published codes (0717T, 0718T) will become effective on July 1, 2022 and mark an important step for the future commercialization of InGeneron’s cell therapy platform, currently under evaluation in ongoing FDA approved trials.

The CPT^® terminology serves as a uniform nomenclature used for medical services and is the most widely accepted medical language for government payers, including Medicare and Medicaid, and commercial health plans to describe healthcare services and procedures for reimbursement.

“The decision by the AMA to issue these new CPT^® codes is a major milestone for InGeneron and advances the potential of innovative and evidence-based stem cell therapies,” said InGeneron Executive Chairman Eckhard Alt, MD PhD. “The issuance of these CPT^® codes marks an important step toward providing patients with the next generation of life changing cell-based therapies that we are developing at InGeneron. Ultimately, with FDA approval of InGeneron’s cell therapy, these new codes would provide access to this therapy to the many patients in the US who suffer from orthopedic conditions that are not properly addressed by current treatment options,” commented Alt.

About the Transpose^® RT System and Current Clinical Trials

InGeneron’s Transpose^® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase^®, a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients' own adipose tissue at point-of-care in less than 90 minutes for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance.
The Transpose^® RT System is being investigated in several FDA-approved clinical trials and is currently available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at www.clinicaltrials.gov under the identifiers NCT03752827, NCT03513731, and NCT03503305.

About InGeneron

InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Having conducted more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA.

www.ingeneron.com